Grand Finale! Shanghai Sun Biotech Shines at CMDAL 2026 with a Well-Received Booth!

On October 17, the 2026 Chinese Medical Association Laboratory Medicine Annual Meeting (CMDAL 2026) & 20th Laboratory and Clinical Medicine Conference, hosted by the Chinese Medical Association and its Laboratory Physicians Branch, wrapped up successfully in Wuxi, Jiangsu Province.

Autumn graces the shores of Taihu Lake. As the verse goes, “Rising waves signal mountain peaks; calm waters remain still when winds subside.” This imagery mirrors laboratory medicine in today’s evolving landscape: forward momentum paired with steady, deep-rooted expertise. Shanghai Sun Biotech was invited to this event, showcasing its UP, UG and UR series coagulation analyzers alongside the UL-2000LAS Lab automation system. Building on its established instrument portfolio, the company also displayed its full range of reagents. Through its integrated hardware and software solutions, Shanghai Sun Biotech demonstrated the robust capabilities of China’s homegrown coagulation diagnostics.

Accumulation · A Full-Tier Product Portfolio, Delivering Core Technology

To meet testing requirements across medical facilities of all sizes, Shanghai Sun Biotech has developed a complete coagulation testing product lineup:

• The UR series and UL-2000LAS Lab automation system deliver automated solutions for large and mid-sized laboratories;

• The UG series features magneto‑optical aggregation detection to handle complex testing scenarios;

• The UP series addresses the routine testing needs of small and medium labs with reliable performance and cost advantages.

Our reagent menu covers coagulation factors, Protein C, Protein S, lupus anticoagulant, anti-Xa activity and other specialized assays. These assays support three key clinical use cases: thromboembolism screening, coagulation factor deficiency diagnosis, and anticoagulation therapy monitoring. Shanghai Sun Biotech is one of the most comprehensive suppliers of specialized coagulation tests in China. By expanding access to these specialized assays, we help healthcare institutions, especially prefecture-level hospitals, to overcome the high costs and supply constraints associated with imported reagents. This brings advanced specialty coagulation testing to frontline clinical care.

Breaking New Ground · Quality First, Embracing AI

While continuously expanding its test menu, Shanghai Sun Biotech prioritizes clinical validation and rigorous quality control as foundational principles. All reagents have undergone multi-center clinical validation at major tertiary hospitals nationwide. Our coagulation products have achieved high scores in China’s External Quality Assessment (EQA) for 17 consecutive years. This consistent, high-quality performance reflects our mature quality management system and delivers reliable results for clinical practice.

Aligning with the conference’s core theme of Artificial Intelligence, Shanghai Sun Biotech is accelerating AI adoption in coagulation testing. To resolve common challenges in specimen quality screening, proprietary algorithms enhance the instrument’s ability to identify interferences including hemolysis, lipemia and icterus. This streamlines automated result review and boosts lab productivity. We also embed disease models and intelligent interpretation tools into the testing workflow, transforming coagulation testing from automated report generation toward intelligent clinical interpretation. This enables high-end coagulation diagnostics to better improve patient care outcomes.

Riding the Momentum · Centered on Clinical Needs, Refining Localized Coagulation Diagnostic Solutions

Throughout the exhibition, numerous industry experts and laboratory clinicians visited our booth for in-depth discussions. Topics covered coagulation technology advances, unmet clinical needs, and innovation for domestic substitution. Attendees praised Shanghai Sun Biotech’s end-to-end, integrated coagulation diagnostic portfolio, as well as our long-term commitment to advancing this specialized field.

Innovation shapes industry trends, and craftsmanship sustains our mission. The CMDAL in Wuxi represented a key platform for Shanghai Sun Biotech to showcase domestic IVD strengths, connect with clinical stakeholders and foster industry collaboration. Moving forward, Shanghai Sun Biotech will continue to focus on precision thrombosis and hemostasis diagnostics, continuously iterate hardware and software products, enrich testing menus, and optimize clinical solutions, empowering clinical precision diagnosis and treatment with increased efficiency, and boosting the domestic in vitro diagnostic industry to new heights.